PRAME, technical only
Use
Preferentially expressed antigen in melanoma (PRAME) is a melanoma-associated antigen that acts as a repressor of the retinoic acid receptor signaling pathway. PRAME stains many melanoma subtypes diffusely positive as well as other malignant tumors such as certain sarcomas, carcinomas, and hematolymphoid neoplasms. PRAME is basally expressed in benign testis, ovary, placenta, adrenals, and endometrium tissues. Technical component only. Pathologist read not included.
Special Instructions
Not provided.
Limitations
This test is technical only, with no pathologist interpretation provided. The absence of pathologist review necessitates supplementary diagnostic, clinical, or pathologic correlation by a qualified healthcare provider.
Methodology
Immunoassay (IHC)
Biomarkers
PRAME
Protein
Result Turnaround Time
2 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (Fixed (Non-FFPE))
Volume
Not provided
Minimum Volume
Not provided
Container
10% neutral buffered formalin (NBF)
Collection Instructions
Fixative should be at a 20:1 fixative to tissue ratio for 6-72 hours (48-72 hours PREFERRED).
Storage Instructions
15°C to 25°C, Specimens may be transferred to 70% alcohol for transportation purposes after fixation in 10% NBF or B plus.
Causes for Rejection
Specimens must be fixed in 10% NBF or B plus. All other fixatives will be rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | ≤ 72 Hours |